ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023
Polypharmacy and multiple sclerosis: A population-based study.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- Trigeminal Neuralgia in Multiple Sclerosis: A Critical Review of the Therapeutic Evidence and the Role of Cerebellopontine Angle Surgical Exploration.Brain sciences · 2026Review
- Population-Based Trends in Antidepressant Dispensing Among Children and Adolescents in Manitoba, Canada.Pharmacoepidemiology and drug safety · 2026Article
- The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.Journal of neurology · 2026Observational
- Associations between medication use and multiple domains of cognitive function in people with multiple Sclerosis.Multiple sclerosis and related disorders · 2026Article
- Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.Frontiers in immunology · 2026Review
- Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.Journal of neurology · 2025Article
- Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis.Neurological research and practice · 2025Review
- Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models.International journal of MS care · 2025Review
- A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.Therapeutic advances in chronic disease · 2025Review
- Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort.Movement disorders clinical practice · 2024Observational
- Antibiotic Utilization Among People With Multiple Sclerosis in the Netherlands, 2018-2020.Pharmacoepidemiology and drug safety · 2024Article
- Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.Frontiers in immunology · 2024Review
- Personality traits in patients with multiple sclerosis: their association with nicotine dependence and polypharmacy.Therapeutic advances in neurological disorders · 2024Article
- Comment on "Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics".Clinical proteomics · 2023Article
- Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.Current neurology and neuroscience reports · 2023Review
- Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis.Journal of clinical medicine · 2023Article
- Data resource profile: PharmaNet, the database for prescription drug dispensing in British Columbia, Canada.International journal of population data science · 2023Article
- Impact of aging on treatment considerations for multiple sclerosis patients.Frontiers in neurology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundLittle is known about polypharmacy and multiple sclerosis (MS).
objectivesTo estimate polypharmacy prevalence in a population-based MS cohort and compare persons with/without polypharmacy.
methodsUsing administrative and pharmacy data from Canada, we estimated polypharmacy prevalence (⩾5 concurrent medications for >30 consecutive days) in MS individuals in 2017. We compared the characteristics of persons with/without polypharmacy and described the number of polypharmacy days, the most common medication classes contributing to polypharmacy and hyper-polypharmacy prevalence (⩾10 medications).
resultsOf 14,227 included individuals (75% women), mean age = 55.4 (standard deviation (SD): 13.2) years; 28% (
conclusionMore than one in four MS persons met criteria for polypharmacy. The odds of polypharmacy were higher for women, older persons, and those with more comorbidities, but lower SES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.